NASDAQ$LFCR
Lifecore Biomedical Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Lifecore Biomedical Inc reported Q2 2025 results with total revenue of $32.6 million and a net loss of $6.6 million.
The company posted an 8% year-over-year revenue increase driven by higher CDMO and HA manufacturing volumes. Gross profit improved to $11.1 million while operating loss widened slightly to $2.0 million due to higher SG&A costs including stock-based compensation. The quarter ended with $9.5 million in cash and compliance with all debt covenants.
- Total revenue rose 8% to $32.6 million versus $30.2 million in Q2 2024, led by CDMO growth.
- Gross margin expanded to 34.0% from 33.0% on favorable product mix and pricing.
- Net loss of $6.6 million compared to prior-year net income of $14.2 million, primarily due to absence of large debt derivative gain.
- Cash position strengthened to $9.5 million after equity offering and lease incentive proceeds.
Headline financials
Revenue & EPS history
Lifecore Biomedical · Revenue · Quarterly
$32.6M
Revenue by segment
Lifecore Biomedical · $32.6M total across 2 segments · Q2 2025
- CDMO$25.6M—78.6%
- HA Manufacturing$6.95M—21.4%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.1%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-0.4%
Avg return
30 days after
40%
25 / 63 earnings
Positive
+19.5%
Q2 2013
Best reaction
-66.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q3 2026 | -3.9% | -13.0% | +8.9% | |
| Q1 2026 | -0.1% | +7.5% | +12.5% | |
| Q4 2025 | -6.3% | -0.3% | -3.0% | |
| Q3 2025 | -22.3% | -8.5% | +7.0% | |
| Q1 2025 | +8.1% | -3.6% | +24.8% | |
| Q4 2024 | -21.0% | -27.0% | -21.0% | |
| Q3 2024 | +8.2% | +15.7% | -5.0% | |
| Q2 2024 | +8.2% | +15.7% | -5.0% | |
| Q1 2024 | +8.2% | +15.7% | -5.0% | |
| Q4 2023 | -13.2% | -13.7% | -16.8% | |
| Q3 2023 | -0.5% | +3.8% | +18.1% | |
| Q2 2023 | -66.7% | -35.1% | -23.6% | |
| Q1 2023 | -5.3% | -5.4% | +4.0% | |
| Q4 2022 | +4.7% | +7.1% | -6.0% | |
| Q3 2022 | -8.3% | -9.6% | -20.8% | |
| Q2 2022 | -1.8% | -8.1% | -2.5% | |
| Q1 2022 | -9.6% | -10.4% | -4.7% | |
| Q4 2021 | -6.8% | -12.4% | -10.5% | |
| Q3 2021 | -10.4% | -10.0% | +12.0% | |
| Q2 2021 | -2.2% | -0.9% | -0.8% | |
| Q1 2021 | +1.2% | +0.8% | -2.7% | |
| Q4 2020 | -14.4% | -9.0% | -9.4% | |
| Q3 2020 | +15.3% | +15.6% | +31.6% | |
| Q2 2020 | -11.3% | -10.5% | -1.0% | |
| Q1 2020 | -3.6% | -6.1% | -9.4% | |
| Q4 2019 | +5.2% | -1.1% | +3.7% | |
| Q3 2019 | -9.3% | -17.5% | -18.7% | |
| Q2 2019 | -12.4% | -3.6% | +8.1% | |
| Q1 2019 | -0.2% | -4.1% | -2.5% | |
| Q4 2018 | -5.7% | -5.3% | -5.3% | |
| Q3 2018 | +6.5% | +3.4% | +1.9% | |
| Q2 2018 | +3.2% | +3.2% | +4.8% | |
| Q1 2018 | +11.3% | +8.4% | +9.6% | |
| Q4 2017 | -7.7% | -9.4% | -8.7% | |
| Q3 2017 | +10.1% | +19.7% | +16.0% | |
| Q2 2017 | -2.5% | -2.2% | -10.9% | |
| Q1 2017 | +5.6% | +5.3% | +4.4% | |
| Q4 2016 | +2.1% | +1.1% | +10.9% | |
| Q3 2016 | +0.5% | — | — | |
| Q2 2016 | -0.1% | — | — | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -1.3% | — | — | |
| Q3 2015 | +1.2% | — | — | |
| Q2 2015 | -1.5% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | +5.0% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +1.1% | — | — | |
| Q1 2014 | -8.4% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q3 2013 | +4.0% | — | — | |
| Q2 2013 | +19.5% | — | — | |
| Q4 2010 | -1.7% | — | — | |
| Q1 2013 | -0.3% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q3 2012 | -0.5% | — | — | |
| Q2 2011 | -0.5% | — | — | |
| Q2 2012 | -0.5% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2010 | +5.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro